Assembly Biosciences, Inc. (NASDAQ:ASMB) Director William R. Ringo sold 1,000 shares of the company’s stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $33.70, for a total value of $33,700.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Assembly Biosciences, Inc. (NASDAQ ASMB) traded down 2.56% during trading on Tuesday, reaching $31.20. The company had a trading volume of 218,898 shares. The stock’s market capitalization is $541.76 million. The firm has a 50-day moving average of $31.28 and a 200-day moving average of $25.26. Assembly Biosciences, Inc. has a 1-year low of $10.93 and a 1-year high of $36.31.

ILLEGAL ACTIVITY NOTICE: This piece of content was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/17/william-r-ringo-sells-1000-shares-of-assembly-biosciences-inc-asmb-stock.html.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Parametric Portfolio Associates LLC boosted its holdings in Assembly Biosciences by 13.6% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 10,078 shares of the biopharmaceutical company’s stock valued at $208,000 after purchasing an additional 1,203 shares in the last quarter. FNY Partners Fund LP purchased a new stake in Assembly Biosciences in the 1st quarter valued at approximately $140,000. Acadian Asset Management LLC boosted its holdings in Assembly Biosciences by 58.2% in the 2nd quarter. Acadian Asset Management LLC now owns 16,336 shares of the biopharmaceutical company’s stock valued at $338,000 after purchasing an additional 6,011 shares in the last quarter. Nationwide Fund Advisors purchased a new stake in Assembly Biosciences in the 2nd quarter valued at approximately $161,000. Finally, Renaissance Technologies LLC purchased a new stake in Assembly Biosciences in the 1st quarter valued at approximately $242,000. 72.27% of the stock is currently owned by institutional investors.

A number of analysts have recently commented on the company. Chardan Capital restated a “buy” rating on shares of Assembly Biosciences in a research note on Sunday, September 17th. BidaskClub upgraded Assembly Biosciences from a “strong sell” rating to a “sell” rating in a research note on Thursday, August 3rd. Finally, Zacks Investment Research upgraded Assembly Biosciences from a “sell” rating to a “hold” rating in a research note on Tuesday, October 10th.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.

Receive News & Ratings for Assembly Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.